ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview

ProQR Therapeutics NV

11/08/2026 13:43

ProQR Therapeutics NV PRQR.OQ PRQR.O is expected to  show a rise in quarterly revenue when it reports  results on August 13 (estimated) for the period ending June 30 2026
The Leiden Zuid-holland-based  company is expected to report a 20.0% increase in revenue to €4.579 million from €3.82 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
​LSEG's mean analyst estimate for ProQR Therapeutics NV is for a loss of 11 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 397.2% above its last closing price of $1.81
Previous quarterly performance (using preferred earnings measure in euros). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.11
-0.12
-0.13
Missed
-8.7
Dec. 31 2026
-0.10
-0.08
Beat
17.2
Sep. 30 2025
-0.11
-0.10
-0.10
Met
2.9​
Jun. 30 2025
-0.09
-0.08
-0.12
Missed
-46.4
​​Mar. 31 2025
-0.11
-0.09
-0.10
Missed
-8.1
Dec. 31 2024
-0.11
-0.09
-0.09
Met
-1.7​
Sep. 30 2024
-0.10
-0.11
-0.10
Beat
5.2
Jun. 30 2024
-0.11
-0.12
-0.03
Beat
75.9
This summary was machine generated August 11 at 12:43 GMT.  All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)